Arch Biopartners Inc.

About Arch Biopartners Inc.

Arch Biopartners is a therapeutic biotech company focused on developing novel, on-target drugs for kidney injury and disease. Their portfolio addresses both acute kidney injury (AKI) and chronic kidney disease (CKD), aiming to improve outcomes for millions of patients worldwide through innovative therapies.

Products & Services

LSALT Peptide (Metablok™):A first-in-class DPEP1 inhibitor designed to protect kidneys from ischemia-reperfusion injury, currently in a global Phase II trial for cardiac surgery-associated AKI (CS-AKI).

Cilastatin:A repurposed DPEP1 inhibitor in a Phase II trial (PONTiAK, 700 patients, CIHR/ACT funded) to prevent toxin-induced AKI caused by antibiotics, chemotherapeutics, and contrast agents.

CKD Platform:A pre-clinical platform targeting IL-32, a cytokine implicated in diabetic kidney disease (DKD), aiming to develop novel therapeutics for chronic kidney disease, the leading cause of kidney failure worldwide.

Specialties

Kidney Therapeutics Acute Kidney Injury (AKI) Chronic Kidney Disease (CKD) Inflammation Biology Diabetic Kidney Disease (DKD) DPEP1 Inhibition IL-32 Targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 600000 MR: - FA: 600,000 CAD FAN: 600000	D: 2025-11-19 FD: 2025-11-19	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 500000 MR: - FA: $500,000 CAD FAN: 500000	D: 2025-11-10 FD: 2025-11-10	1 investors
3	RT: Grant T: - FT: Grant	A: 4000000 MR: - FA: up to $4,000,000 FAN: 4000000	D: 2023-03-23 FD: 2023-03-23	1 investors

Private Placement Latest

2025-11-19

$600K

1 investor (Pro only)

Private Placement 2025-11-10

$500K

Grant 2023-03-23

$4.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard Muruve

CEO

A

Andrew Bishop

CFO

R

Richard Rossman

Director

C

Claude Allary

Director

D

Dr. David Luke

Strategic Advisor

F

Farris Smith

Strategic Advisor

View 12 more team members with Pro

Unlock Full Team Directory

Recent News